Sichenzia Ross Friedman Ference LLP Represents Tonix Pharmaceuticals Holding Corp. on $20.1M Public Offering
Press Release – New York – July 17, 2015 – New York-based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the firm represented Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage pharmaceutical company focused on products to treat common disorders of the central nervous system, in an underwritten public offering of 2,325,000 shares of its common stock, as well as the sale of 348,750 additional shares pursuant to the full exercise of the over-allotment option granted to the underwriters. The shares were sold to the public at an offering price of $7.50 per share resulting in gross proceeds to Tonix of approximately $20.1 million.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Marc J. Ross and James M. Turner. Roth Capital Partners and Oppenheimer & Co. acted as joint underwriters and Janney Montgomery Scott acted as co-manager in this offering.
- Sichenzia Ross Ference LLP Announces Over 80 Capital Markets Transactions Valued Over $2 Billion at the Closing of 2021 - January 13, 2022
- Sichenzia Ross Ference LLP Adds Two Key Additions to its Corporate and Securities Law Team - January 11, 2022
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $9.8 Million Underwritten Offering of BiondVax Pharmaceuticals Ltd. - December 30, 2021